Hong Kong

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• IgA nephropathy2 trials

Phase

• Phase 21 trial
• Phase 31 trial

Status

• Completed2 trials

Lead sponsor

• Travere Therapeutics, Inc.2 trials

Closed trials

• Completed

  A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

  NCT05856760· Phase 2· Travere Therapeutics, Inc.· Source

• Completed

  A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

  NCT03762850· Phase 3· Travere Therapeutics, Inc.· Source